ORIGINAL ARTICLE

Localisation of members of the vascular endothelial growth factor (VEGF) family and their receptors in human atherosclerotic arteries

F Belgore¹, A Blann¹, D Neil², A S Ahmed³, G Y H Lip¹

¹ Haemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham B18 7QH, UK
² Department of Histopathology, University of Birmingham, Birmingham B15 2TT, UK
³ Department of Reproductive and Vascular Biology, Division of Reproduction and Child Health, University of Birmingham, Birmingham B15 2TG, UK

Correspondence to:
Correspondence to:
Professor G Y H Lip
Haemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham B18 7QH, UK; g.y.h.lip{at}bham.ac.uk

Background: Vascular endothelial growth factor (VEGF) mediates endothelial cell mitogenesis and enhances vascular permeability. The existence of single or multiple VEGF isoforms and receptors suggests that these proteins may have overlapping but distinct functions, which may be reflected in their cell expression and distribution.

Methods: The localisation of VEGFs A–C and their receptors (VEGFRs 1–3, respectively) in 30 fresh human atherosclerotic arteries, 15 normal uterine arteries, and 15 saphenous veins using immunohistochemistry and western blotting.

Results: Saphenous veins showed no staining for VEGF-B or VEGFR-2. Smooth muscle cells (SMCs) showed the strongest staining for VEGF-A, VEGF-B, VEGFR-1, and VEGFR-2 in all specimens. Conversely, VEGFR-3 and VEGF-C were predominately localised to the endothelial vasa vasorum in normal arteries, whereas medial SMCs showed the strongest staining in atherosclerotic arteries. Western blotting showed variations in VEGF protein localisation, with lower amounts of VEGF-B and VEGF-C in saphenous veins, compared with arterial tissue. Amounts of VEGF-C were lower than those of VEGF-A and VEGF-B in all specimens.

Conclusion: This study provides direct evidence of the presence of VEGF proteins and receptors in human physiology and pathology, with variations in both the amounts of VEGF proteins expressed and their cellular distribution in normal arteries compared with atherosclerotic arteries. The presence of VEGFs A–C and their receptors in normal arterial tissue implies that VEGF functions may extend beyond endothelial cell proliferation. Reduced VEGFR-2 staining in atherosclerotic arteries may have implications for the atherosclerosis process and the development of vascular disease and its complications.

Keywords: VEGF; atherosclerosis; angiogenesis; cardiovascular disease

Abbreviations: AAA, abdominal aortic aneurysm; AEC, 3-amino-9-ethylcarbazole; DAB, diaminobenzidine; ECM, extracellular matrix; PBS, phosphate buffered saline; SMC, smooth muscle cell; TAH, total abdominal hysterectomy; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor; VVS, varicose vein stripping

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Tedesco, M. M., Terashima, M., Blankenberg, F. G., Levashova, Z., Spin, J. M., Backer, M. V., Backer, J. M., Sho, M., Sho, E., McConnell, M. V., Dalman, R. L. (2009). Analysis of In Situ and Ex Vivo Vascular Endothelial Growth Factor Receptor Expression During Experimental Aortic Aneurysm Progression. Arterioscler. Thromb. Vasc. Bio. 29: 1452-1457 [Abstract] [Full Text]  
• Morrow, D., Cullen, J. P., Liu, W., Guha, S., Sweeney, C., Birney, Y. A., Collins, N., Walls, D., Redmond, E. M., Cahill, P. A. (2009). Sonic Hedgehog Induces Notch Target Gene Expression in Vascular Smooth Muscle Cells via VEGF-A. Arterioscler. Thromb. Vasc. Bio. 29: 1112-1118 [Abstract] [Full Text]  
• Hauer, A. D., van Puijvelde, G. H.M., Peterse, N., de Vos, P., van Weel, V., van Wanrooij, E. J.A., Biessen, E. A.L., Quax, P. H.A., Niethammer, A. G., Reisfeld, R. A., van Berkel, T. J.C., Kuiper, J. (2007). Vaccination Against VEGFR2 Attenuates Initiation and Progression of Atherosclerosis. Arterioscler. Thromb. Vasc. Bio. 27: 2050-2057 [Abstract] [Full Text]  
• Doyle, B., Caplice, N. (2007). Plaque Neovascularization and Antiangiogenic Therapy for Atherosclerosis. J Am Coll Cardiol 49: 2073-2080 [Abstract] [Full Text]  
• Chyu, K.-Y., Shah, P. K. (2007). Choking off Plaque Neovascularity: A Promising Atheroprotective Strategy or A Double-Edged Sword?. Arterioscler. Thromb. Vasc. Bio. 27: 993-995 [Full Text]  
• Petrovan, R. J., Kaplan, C. D., Reisfeld, R. A., Curtiss, L. K. (2007). DNA Vaccination Against VEGF Receptor 2 Reduces Atherosclerosis in LDL Receptor-Deficient Mice. Arterioscler. Thromb. Vasc. Bio. 27: 1095-1100 [Abstract] [Full Text]  
• Herrmann, J., Lerman, L. O., Mukhopadhyay, D., Napoli, C., Lerman, A. (2006). Angiogenesis in Atherogenesis. Arterioscler. Thromb. Vasc. Bio. 26: 1948-1957 [Abstract] [Full Text]  
• Khurana, R., Simons, M., Martin, J. F., Zachary, I. C. (2005). Role of Angiogenesis in Cardiovascular Disease: A Critical Appraisal. Circulation 112: 1813-1824 [Abstract] [Full Text]